Two-Phase Business Strategy to Reduce Investor Risk

 

Phase 1:

Our proprietary API and SaaS Cloud platform empowers AI and Machine Learning to convert data from legacy analog medical devices into actionable insights—diagnostic, descriptive, predictive, and prescriptive—that aid medical professionals in enhancing patient health and life quality. We begin with a focus on cardiovascular disease, leveraging our access to data and experienced teams to validate our personalized health solutions. Cardiovascular disease remains the leading cause of death in America and represents the highest cost for the Centers for Medicare & Medicaid Services (CMS).

 

By partnering with traditional medical device companies, we transition legacy analog products into digital formats, thereby enhancing outcomes and creating profitability from previously unmonetized data. This strategy not only shortens the sales cycle but also fosters partnerships with medical device manufacturers, granting us access to meta-ML/AI training data and accelerating early annuitized cash flows through licensing.

 

Phase 2:  

The drug research and development landscape is increasingly complex, lengthy, and capital-intensive, with higher failure rates. Our proprietary, patent-pending Digital Twin technology and accompanying Hologram facilitate simultaneous global collaboration in the quest to cure the world’s most deadly diseases. By assisting drug companies in discovering derivative applications for existing drug portfolios—such as the well-known examples of Viagra and Botox—our platform significantly shortens development times.

 

With the ability to run clinical trials at potentially millions of times the speed of current technologies, we increase scalability while reducing risks and costs through bio-molecular level pre-trial drug interaction predictors. Our approach helps scientists “fail faster,” avoiding costly dead ends in the drug development process, and accelerates R&D by providing deep insights into drug mechanics, combining biology, chemistry, physics, mathematics, and individualized genomics.

 

Our proprietary platform also capitalizes on recent advancements in quantum genomics, machine learning, and artificial intelligence (and soon quantum computing), enabling the customization of medicines and therapies at the individual level for the world’s most elusive and deadly diseases.

 

Proof of Concept:

Our Proof of Concept (POC) showcased the platform's capabilities by analyzing well-known pain medications, including Aspirin, Tylenol, and Acetaminophen, to demonstrate bio-similarity and dissimilarity. The successful results provided valuable insights previously unseen by drug manufacturers and researchers, underscoring the robustness of the xBxBio platform and its potential to expedite the research and development of both existing and new drugs.